Skip to content

GenomeWeb – Proteomics International to Test Kidney Disease Test as CDx for Investigational Treatment

Proteomics International Laboratories announced today that it has signed an agreement to evaluate its PromarkerD test in clinical trials of Dimerix’s investigational chronic kidney disease drug DMX-200.

Article: Proteomics International to Test Kidney Disease Test as CDx for Investigational Treatment